Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review
The application of immune checkpoint inhibitors has proven to be an effective treatment for cancer. Immune checkpoints such as programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoglobulin-3 (TIM-3)...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2024-04-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://bjbms.org/ojs/index.php/bjbms/article/view/10339 |
| _version_ | 1797201498788069376 |
|---|---|
| author | Yu-Quan Li Xue-Mei Chen Gui-Fei Si Xue-Min Yuan |
| author_facet | Yu-Quan Li Xue-Mei Chen Gui-Fei Si Xue-Min Yuan |
| author_sort | Yu-Quan Li |
| collection | DOAJ |
| description |
The application of immune checkpoint inhibitors has proven to be an effective treatment for cancer. Immune checkpoints such as programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoglobulin-3 (TIM-3), T-cell immunoglobulin and ITIM domain (TIGIT), and lymphocyte activation gene-3 (LAG-3) have received extensive attention, and the efficacy of antibodies or inhibitors against these checkpoints (either alone or in combination) has been evaluated in many tumors. This paper provides a brief overview of the PD-1 and LAG-3 checkpoints, and then shifts focus to the combined use of PD-1 and LAG-3 antibodies in both in vivo and in vitro experiments. In the in vitro experiments, we examined the correlation between the expression and activation of these inhibitors on T cells, and also assessed toxicity in animals in preparation for in vivo experiments. The effects of the combined use of PD-1 and LAG-3 antibodies were then summarized in animal models of melanoma, MC38 carcinoma, and other tumors. In clinical studies, the combined application of these antibodies was assessed in patients with melanoma, colorectal, breast, and renal cell cancers, as well as other solid tumors. In general, the combination of PD-1 and LAG-3 antibodies has shown promising results in both in vivo and in vitro studies.
|
| first_indexed | 2024-04-24T07:48:30Z |
| format | Article |
| id | doaj.art-07da0ce7416b417baaa5e1cbbf0deb18 |
| institution | Directory Open Access Journal |
| issn | 2831-0896 2831-090X |
| language | English |
| last_indexed | 2024-04-24T07:48:30Z |
| publishDate | 2024-04-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj.art-07da0ce7416b417baaa5e1cbbf0deb182024-04-18T14:50:30ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2024-04-0110.17305/bb.2024.10339Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A reviewYu-Quan Li0Xue-Mei Chen1Gui-Fei Si2Xue-Min Yuan3School of Clinical Medicine, Shandong Second Medical University, Weifang, ChinaSchool of Clinical Medicine, Shandong Second Medical University, Weifang, ChinaSchool of Clinical Medicine, Shandong Second Medical University, Weifang, ChinaLinyi People’s Hospital, Linyi, China The application of immune checkpoint inhibitors has proven to be an effective treatment for cancer. Immune checkpoints such as programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoglobulin-3 (TIM-3), T-cell immunoglobulin and ITIM domain (TIGIT), and lymphocyte activation gene-3 (LAG-3) have received extensive attention, and the efficacy of antibodies or inhibitors against these checkpoints (either alone or in combination) has been evaluated in many tumors. This paper provides a brief overview of the PD-1 and LAG-3 checkpoints, and then shifts focus to the combined use of PD-1 and LAG-3 antibodies in both in vivo and in vitro experiments. In the in vitro experiments, we examined the correlation between the expression and activation of these inhibitors on T cells, and also assessed toxicity in animals in preparation for in vivo experiments. The effects of the combined use of PD-1 and LAG-3 antibodies were then summarized in animal models of melanoma, MC38 carcinoma, and other tumors. In clinical studies, the combined application of these antibodies was assessed in patients with melanoma, colorectal, breast, and renal cell cancers, as well as other solid tumors. In general, the combination of PD-1 and LAG-3 antibodies has shown promising results in both in vivo and in vitro studies. https://bjbms.org/ojs/index.php/bjbms/article/view/10339Immunotherapyprogrammed cell death protein 1 (PD-1)programmed cell death protein 1 ligand 1 (PD-L1)lymphocyte activation gene-3 (LAG-3)combination therapy |
| spellingShingle | Yu-Quan Li Xue-Mei Chen Gui-Fei Si Xue-Min Yuan Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review Biomolecules & Biomedicine Immunotherapy programmed cell death protein 1 (PD-1) programmed cell death protein 1 ligand 1 (PD-L1) lymphocyte activation gene-3 (LAG-3) combination therapy |
| title | Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review |
| title_full | Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review |
| title_fullStr | Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review |
| title_full_unstemmed | Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review |
| title_short | Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review |
| title_sort | progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment a review |
| topic | Immunotherapy programmed cell death protein 1 (PD-1) programmed cell death protein 1 ligand 1 (PD-L1) lymphocyte activation gene-3 (LAG-3) combination therapy |
| url | https://bjbms.org/ojs/index.php/bjbms/article/view/10339 |
| work_keys_str_mv | AT yuquanli progressoflymphocyteactivationgene3andprogrammedcelldeathprotein1antibodiesforcancertreatmentareview AT xuemeichen progressoflymphocyteactivationgene3andprogrammedcelldeathprotein1antibodiesforcancertreatmentareview AT guifeisi progressoflymphocyteactivationgene3andprogrammedcelldeathprotein1antibodiesforcancertreatmentareview AT xueminyuan progressoflymphocyteactivationgene3andprogrammedcelldeathprotein1antibodiesforcancertreatmentareview |